Ebola outbreak: Japan offers experimental anti-flu drug to World Health Organisation for Ebola treatment
Favipiravir has not been tested on Ebola but scientists say it could work
Monday 25 August 2014
Japan is offering an experimental anti-viral drug called favipiravir as a possible treatment for the Ebola virus.
The drug, known under the brand name Avignan, has been approved by Japan’s health ministry for use against flu but has not been tested on humans with Ebola.
The Chief Cabinet Secretary Yoshihide Suga said its manufacturers, a subsidiary of Fujifilm Holdings Corp, can ship the drug at any time on the request of the World Health Organisation (WHO).
Almost 1,500 people have so far been killed by the Ebola outbreak since March in Guinea, Liberia and Sierra Leone.
There is known cure or treatment for the disease, which has a fatality rate estimated at between 60 and 90 per cent.
Despite the recovery of the two American humanitarian workers treated with another experimental drug, ZMapp, a Spanish priest and Liberian doctor given the treatment have died.
Read more: First Briton to contract deadly virus now in London hospital isolation unit
William Pooley, the first Briton to contract Ebola since outbreak, described as a hero by colleagues
Disease claims first European victim as Spanish priest infected in Liberia dies
Ebola outbreak: What is ZMapp and could the experimental treatment stop the disease?
It was not possible to determine whether the American workers had recovered naturally like other Ebola survivors or whether it was due to the serum.
Spanish priest Miguel Pajares, who has died from Ebola, with a patient in Liberia Only six people in the world are known to have received ZMapp and the small supply is now said to be exhausted.
Fujifilm is in talks with the US Food and Drug Administration over the clinical testing of favipiravir in treating Ebola, company spokesman Takao Aoki said.
He said Ebola and influenza viruses are the same general type and a similar response can theoretically be expected from both.
Favipiravir inhibits viral gene replication within infected cells to prevent propagation, while other anti-viral drugs often are designed to inhibit the release of new viral particles to prevent the spread of infection, the company said.
It has enough stock of favipiravir for more than 20,000 patients.
Mr Suga said Japan is waiting for a decision by WHO that would provide greater guidance on the use of untested drugs against Ebola.
In case of an emergency, Japan may respond to individual requests before any further decision by WHO, he said.
The UN agency said earlier this month that it is ethical to use untested drugs on Ebola patients given the magnitude of the outbreak.
Although several drugs are being developed for the treatment of the virus, they are still in the early stages.
The first Briton to contract the deadly virus arrived back in England from Sierra Leone on Sunday.
The patient, named as 29-year-old William Pooley, had been working with victims as a nurse and is being treated in a specialist isolation unit.
Additional reporting by AP
- 1 Game of Thrones season 6: Jon Snow theorists believe Ned Stark's son may have a twin sister
- 2 Artist takes LSD, draws herself over different stages of the 9-hour trip to show its effects
- 4 iPhone 6s camera: features to include 4K video camera and flash for selfies
- 5 A pint of water every day is the key to losing weight, scientists say
Miley Cyrus address Robin Thicke VMA controversy: ‘He wanted me as naked as possible, but I got the heat because I’m a woman’
Most expensive city to live in for expatriates: Luanda, Angola takes number one spot with Hong Kong and Zurich in top three
If Surrey were Syria: Social experiment shows what it's like to live under siege
Irish tourist filmed fighting with shopkeepers in Turkey says they 'messed with the wrong man'
House of Lords: Outcry as donors, fixers and MPs caught up in expenses scandal get peerages
Dresden riots: Protesters in Germany attack refugee buses shouting 'foreigners out'
France train shooting: US soldiers speak of the moment they stopped gunman and 'beat him until he was unconscious'
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
£32000 - £40000 per annum: Recruitment Genius: With extensive experience and a...
Unpaid - £4 lunch allowance plus travel to and from work: Barnardo's: Purpose ...
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...